Proton pump inhibitor (PPI) therapy does not contribute to increased risk of fractures, with a new study suggesting that its long-term use has no effect on bone mineral density (BMD) or bone strength.
Combining all-trans retinoic acid (ATRA) with ursodeoxycholic acid (UDCA) does not significantly reduce alkaline phosphatase levels in patients with primary sclerosing cholangitis (PSC), according to the results of a human pilot study. However, the combination therapy significantly lowers alanine aminotransferase and the bile acid intermediate 7α-hydroxy-4-cholesten-3-one (C4).
There is a high utilization rate of dual antiplatelet therapy (DAPT) following coronary artery bypass grafting (CABG) in patients with diabetes, according to a secondary analysis of the FREEDOM* trial. Moreover, there are no significant associations seen with all-cause mortality, myocardial infarction (MI) or stroke when compared with aspirin monotherapy.
Short-term use of the norepinephrine reuptake inhibitor phentermine in addition to standard of care (SOC) lifestyle modification therapy may lead to greater weight loss in adolescents with obesity compared with SOC alone, according to a study.
The intra-articular steroid preparation methylprednisolone acetate is as effective as triamcinolone acetonide in the treatment of chronic inflammatory arthritis, according to the results of a trial.
The use of lithium does not appear to have a protective effect against dementia among elderly patients suffering from bipolar disorder, according to a retrospective cohort study.
In patients receiving palliative care, treatment with oral risperidone or haloperidol does not appear to reduce symptoms of delirium associated with distress, according to a study.
The use of cyclosporine may offer mortality benefit in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), a recent study has found.
Combination therapy with rosuvastatin and ezetimibe is superior to rosuvastatin monotherapy, showing better lipid-lowering efficacy and target achievement rates in patients with high cardiovascular risk, according to the results of a placebo-controlled, multicentre study.
Higher prescription opioid dose may be related to worse patient-reported pain outcomes and higher healthcare utilization, a study suggests.